Low-dose Brachytherapy Seen as Viable Choice for Lower Risk Patients, Long-term Study Finds

Low-dose Brachytherapy Seen as Viable Choice for Lower Risk Patients, Long-term Study Finds
Patients with low-to-intermediate prostate cancer who receive low-dose permanent brachytherapy, a type of radiation therapy, have excellent outcomes in the long run, according to data recently presented at the American Society for Radiation Oncology (ASTRO) 2017 Annual Conference in San Diego, California. At nine years of follow-up, only a minority — 11-14 percent — of patients treated

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *